Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

FDA chief says long-awaited opioid review still in the works

The head of the Food and Drug Administration says a government review of prescription opioid medications, including their risks and contribution to the U.S. overdose epidemic, is still underway

The Independent UK

Pharmaceuticals giant acquires California counterpart for £221.5m

Med-Pharmex employs around 130 people

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Khiron Q2 Revenue Grows 60% YoY, Despite Decline In Medical Cannabis Sales In Germany

Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX: KHRNF) (Frankfurt:A2JMZC) Q2 2022 total revenue was CA$4.5 million ($3.45 million), up 60% year-over-year, driven by growth in the medical cannabis segment in Colombia and the United Kingdom.

Benzinga

Should you get a Covid-19 booster now, or wait until the fall?

As we gear up for another wave of Covid-19 this fall, experts say you should definitely be prepared to get a booster shot. Here's when you should get it.

Inverse

Moderna's COVID vaccine lawsuit looks ahead to future markets

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

Axios

J&J continues to sell talc-based baby powder in India, despite discontinuing in U.S. and Canada

Company says India is part of global transition to cornstarch-based powder

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Q&A: The new COVID vaccine booster is coming. Should you get it?

The COVID-19 vaccine is getting an upgrade.

Tribune News Service

Bayer initiates asundexian Phase III study program

Germany's Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

Reuters

AstraZeneca boss uncertain if yearly Covid-19 boosters for healthy are good use of resources

The chief executive officer believes most of the vaccinated population now has a "foundation immunity against severe disease"

Wales Online

Virginia health officials projecting first decrease in overdose deaths since before the pandemic

NORFOLK, Va. — New data on fatal drug overdoses in Virginia suggests this year could be the first time there’s been a decrease in deaths since 2018.

Tribune News Service

AstraZeneca boss unsure if annual Covid-19 boosters are good use of resources

Chief executive officer Pascal Soriot said he believes most of the vaccinated population has a ‘foundation immunity against severe disease’.

The Independent UK

Indian pharma company taken to court over freebies to doctors

Indian authorities are probing allegations that a drug company bribed doctors to promote its anti-fever pills – the latest controversy involving the country’s pharmaceuticals industry.

Radio France Internationale

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Asharq Al-Awsat

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

StockNews.com

Should You Buy Eargo After the FDA Ruling on Hearing Aids?

Hearing aid maker Eargo (EAR) reported disappointing second-quarter results. And analysts seem bearish about the company’s growth prospects. However, EAR climbed considerably following the FDA approval for over-the-counter hearing aid sales. After gaining nearly 198% over the past month, is EAR still a buy now? Read more to find out….

Wales Online

US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

The Independent UK

Pfizer asks EU drug regulator to OK tweaked COVID vaccine

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Is This Eye Care Stock a Buy as It Strikes $770M Buyout?

Swiss eye care company Alcon (ALC) recently announced that it would acquire Aerie Pharmaceuticals (AERI) for $770 million. The deal is expected to help bolster ALC’s expansion into the ophthalmic pharmaceutical space. So, will it be wise to invest in the stock now? Read on to learn our view….

The Independent UK

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

Evening Standard

Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine

Moderna seeks unspecified damages in lawsuit over rivals’ jab

Bangkok Post

Thonburi Healthcare chairman resigns after market ban

Dr Boon Vanasin, the founder and chairman of Thonburi Healthcare Group (THG), is resigning from the company’s board as he faces a market ban in connection with claims he made last year about the purchase of Pfizer coronavirus vaccines.

Tribune News Service

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Bangkok Post

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

The Independent UK

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

1 … 132 133 134 135

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.